These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22939562)

  • 1. Galectin-3 in cardiovascular disease: a possible window into early myocardial fibrosis.
    Morrow DA; O'Donoghue ML
    J Am Coll Cardiol; 2012 Oct; 60(14):1257-8. PubMed ID: 22939562
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunoanalytical characteristics of galectin-3].
    Desbène C; Gaillard O
    Ann Biol Clin (Paris); 2014; 72(4):491-9. PubMed ID: 25119810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
    López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
    Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
    Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
    Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices.
    Wu CK; Su MY; Lee JK; Chiang FT; Hwang JJ; Lin JL; Chen JJ; Liu FT; Tsai CT
    Sci Rep; 2015 Nov; 5():17007. PubMed ID: 26582585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical experience using galectin-3 in heart failure.
    McCullough PA
    Clin Chem Lab Med; 2014 Oct; 52(10):1425-31. PubMed ID: 24810562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of galectin-3 in patients with heart failure.
    Bošnjak I; Selthofer-Relatić K; Včev A
    Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms.
    Numano F; Shimizu C; Jimenez-Fernandez S; Vejar M; Oharaseki T; Takahashi K; Salgado A; Tremoulet AH; Gordon JB; Burns JC; Daniels LB
    Int J Cardiol; 2015 Dec; 201():429-37. PubMed ID: 26313861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
    Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
    Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure?
    Lala RI; Darabantiu D; Pilat L; Puschita M
    Arq Bras Cardiol; 2016 Feb; 106(2):121-9. PubMed ID: 26760784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis.
    Chen A; Hou W; Zhang Y; Chen Y; He B
    Int J Cardiol; 2015 Mar; 182():168-70. PubMed ID: 25577755
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients.
    Gruson D; Ferracin B; Ahn SA; Rousseau MF
    Int J Cardiol; 2015 Jun; 189():185-7. PubMed ID: 25897901
    [No Abstract]   [Full Text] [Related]  

  • 13. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.
    Lok SI; Nous FM; van Kuik J; van der Weide P; Winkens B; Kemperman H; Huisman A; Lahpor JR; de Weger RA; de Jonge N
    Eur J Cardiothorac Surg; 2015 Sep; 48(3):407-15. PubMed ID: 25609773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 in heart failure: high levels are associated with all-cause mortality.
    Ueland T; Aukrust P; Broch K; Aakhus S; Skårdal R; Muntendam P; Gullestad L
    Int J Cardiol; 2011 Aug; 150(3):361-4. PubMed ID: 21641051
    [No Abstract]   [Full Text] [Related]  

  • 16. Galectin-3, a prognostic marker--and a therapeutic target?
    Pereira AR; Menezes Falcão L
    Rev Port Cardiol; 2015 Mar; 34(3):201-8. PubMed ID: 25746675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3: a modifiable risk factor in heart failure.
    de Boer RA; van der Velde AR; Mueller C; van Veldhuisen DJ; Anker SD; Peacock WF; Adams KF; Maisel A
    Cardiovasc Drugs Ther; 2014 Jun; 28(3):237-46. PubMed ID: 24789662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3, new potential therapeutic target for cardiac remodelling.
    Tao H; Shi KH; Yang JJ
    Eur J Heart Fail; 2013 Jun; 15(6):709. PubMed ID: 23537546
    [No Abstract]   [Full Text] [Related]  

  • 19. Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study.
    Piper SE; de Courcey J; Sherwood RA; Amin-Youssef GF; McDonagh TA
    Int J Cardiol; 2016 Mar; 207():279-81. PubMed ID: 26808993
    [No Abstract]   [Full Text] [Related]  

  • 20. Galectin 3 in heart failure.
    Wiwanitkit V
    Clin Res Cardiol; 2010 Aug; 99(8):527; author reply 529. PubMed ID: 20372914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.